Tags : Bridge Biotherapeutics

Bridge Biotherapeutics Signs a License Agreement with Konkuk University for

Shots: Konkuk University to receive $0.25M upfront, ~$8.1M development and commercial milestones while Bridge Biotherapeutics to get WW exclusive license for the compound and will lead preclinical and development process of the therapy Additionally, in 2019, Bridge Biotherapeutics signed a license agreement with Boehringer Ingelheim to develop BBT-877, an autotaxin inhibitor targeting fibrosing interstitial lung […]Read More

Boehringer Ingelheim Signs a Worldwide License Agreement with Bridge Biotherapeutics

Shots: Bridge to receive $50.66M as up front and near-term payments, up to $1.23B based on development, regulatory, and commercial milestones and royalties on sales The focus of the collaboration is to develop Bridge’s BBT-877 candidate and expand BI’s pipeline of fibrosing interstitial lung diseases in developing therapies for patients with Idiopathic Pulmonary Fibrosis (IPF)  […]Read More